91 related articles for article (PubMed ID: 26524537)
1. A multimodal Pepstatin A peptide-based nanoagent for the molecular imaging of P-glycoprotein in the brains of epilepsy rats.
Yu X; Wang J; Liu J; Shen S; Cao Z; Pan J; Zhou S; Pang Z; Geng D; Zhang J
Biomaterials; 2016 Jan; 76():173-86. PubMed ID: 26524537
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of p38 mitogen-activated protein kinase signaling reduces multidrug transporter activity and anti-epileptic drug resistance in refractory epileptic rats.
Shao Y; Wang C; Hong Z; Chen Y
J Neurochem; 2016 Mar; 136(5):1096-105. PubMed ID: 26677173
[TBL] [Abstract][Full Text] [Related]
3. Drug transporters are altered in brain, liver and kidney of rats with chronic epilepsy induced by lithium-pilocarpine.
Guo Y; Jiang L
Neurol Res; 2010 Feb; 32(1):106-12. PubMed ID: 19570321
[TBL] [Abstract][Full Text] [Related]
4. Construction of Pepstatin A-Conjugated ultrasmall SPIONs for targeted positive MR imaging of epilepsy-overexpressed P-glycoprotein.
Du C; Wang J; Liu X; Li H; Geng D; Yu L; Chen Y; Zhang J
Biomaterials; 2020 Feb; 230():119581. PubMed ID: 31718885
[TBL] [Abstract][Full Text] [Related]
5. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats.
van Vliet EA; van Schaik R; Edelbroek PM; Voskuyl RA; Redeker S; Aronica E; Wadman WJ; Gorter JA
J Pharmacol Exp Ther; 2007 Jul; 322(1):141-7. PubMed ID: 17392402
[TBL] [Abstract][Full Text] [Related]
6. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.
Kwan P; Brodie MJ
Epilepsia; 2005 Feb; 46(2):224-35. PubMed ID: 15679503
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats.
van Vliet EA; van Schaik R; Edelbroek PM; Redeker S; Aronica E; Wadman WJ; Marchi N; Vezzani A; Gorter JA
Epilepsia; 2006 Apr; 47(4):672-80. PubMed ID: 16650133
[TBL] [Abstract][Full Text] [Related]
8. Functionalized nanocarrier combined seizure-specific vector with P-glycoprotein modulation property for antiepileptic drug delivery.
Liu J; He Y; Zhang J; Li J; Yu X; Cao Z; Meng F; Zhao Y; Wu X; Shen T; Hong Z
Biomaterials; 2016 Jan; 74():64-76. PubMed ID: 26447556
[TBL] [Abstract][Full Text] [Related]
9. The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.
Brandt C; Bethmann K; Gastens AM; Löscher W
Neurobiol Dis; 2006 Oct; 24(1):202-11. PubMed ID: 16928449
[TBL] [Abstract][Full Text] [Related]
10. Multimodal SPION-CREKA peptide based agents for molecular imaging of microthrombus in a rat myocardial ischemia-reperfusion model.
Song Y; Huang Z; Xu J; Ren D; Wang Y; Zheng X; Shen Y; Wang L; Gao H; Hou J; Pang Z; Qian J; Ge J
Biomaterials; 2014 Mar; 35(9):2961-70. PubMed ID: 24393265
[TBL] [Abstract][Full Text] [Related]
11. Emodin plays an interventional role in epileptic rats via multidrug resistance gene 1 (MDR1).
Yang T; Kong B; Kuang Y; Cheng L; Gu J; Zhang J; Shu H; Yu S; Yang X; Cheng J; Huang H
Int J Clin Exp Pathol; 2015; 8(3):3418-25. PubMed ID: 26045880
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of tetrandrine on refractory epilepsy via suppressing P-glycoprotein.
Chen Y; Xiao X; Wang C; Jiang H; Hong Z; Xu G
Int J Neurosci; 2015; 125(9):703-10. PubMed ID: 25233150
[TBL] [Abstract][Full Text] [Related]
13. Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients.
Mosyagin I; Runge U; Schroeder HW; Dazert E; Vogelgesang S; Siegmund W; Warzok RW; Cascorbi I
Epilepsia; 2008 Sep; 49(9):1555-61. PubMed ID: 18494787
[TBL] [Abstract][Full Text] [Related]
14. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine.
Marchi N; Guiso G; Rizzi M; Pirker S; Novak K; Czech T; Baumgartner C; Janigro D; Caccia S; Vezzani A
Epilepsia; 2005 Oct; 46(10):1613-9. PubMed ID: 16190932
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models.
Uchida Y; Ohtsuki S; Terasaki T
Drug Metab Dispos; 2014 Oct; 42(10):1719-26. PubMed ID: 25061162
[TBL] [Abstract][Full Text] [Related]
16. The transport of antiepileptic drugs by P-glycoprotein.
Zhang C; Kwan P; Zuo Z; Baum L
Adv Drug Deliv Rev; 2012 Jul; 64(10):930-42. PubMed ID: 22197850
[TBL] [Abstract][Full Text] [Related]
17. Intractable epilepsy and the P-glycoprotein hypothesis.
Wang GX; Wang DW; Liu Y; Ma YH
Int J Neurosci; 2016; 126(5):385-92. PubMed ID: 26000919
[TBL] [Abstract][Full Text] [Related]
18. Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions.
Lazarowski A; Czornyj L
Drug Metabol Drug Interact; 2011; 26(1):21-6. PubMed ID: 21557674
[TBL] [Abstract][Full Text] [Related]
19. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes.
Nieto Montesinos R; Béduneau A; Pellequer Y; Lamprecht A
J Control Release; 2012 Jul; 161(1):50-61. PubMed ID: 22562066
[TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.
van Vliet EA; Zibell G; Pekcec A; Schlichtiger J; Edelbroek PM; Holtman L; Aronica E; Gorter JA; Potschka H
Neuropharmacology; 2010 Feb; 58(2):404-12. PubMed ID: 19786037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
